Product Description
Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. Unlike marketed GnRH agonists, Linzagolix has the potential to be administered orally once a day, with symptoms relieved within days, while potentially mitigating the initial worsening of symptoms often associated with GnRH agonist treatments. (Sourced from: https://www.obseva.com/linzagolix/)
Mechanisms of Action: GnRH Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden
Approved Indications: None
Known Adverse Events: None
Company: ObsEva
Company Location: PLAN-LES-OUATES V8 1228
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Austria, Bulgaria, Czech Republic, France, Japan, Poland, Romania, Spain, Ukraine, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Endometriosis|Injuries/wounds Unspecified|Leiomyoma|Menorrhagia|Myofibroma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031220180 | P3 |
Recruiting |
Menorrhagia |
2025-05-31 |
|
KLH2301 | P3 |
Active, not recruiting |
Myofibroma|Menorrhagia|Leiomyoma |
2025-05-01 |
35% |
jRCT2031220181 | P3 |
Recruiting |
Menorrhagia |
2024-09-30 |
|
KLH2302 | P3 |
Active, not recruiting |
Menorrhagia|Leiomyoma|Myofibroma |
2024-09-01 |
35% |